Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
Bristol-Myers Squibb Co
BMY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 43.30 | 0.53 1.24% | 3.23% | 11,130,086 | 13.2M |
Market data is delayed by at least 20 minutes.
| Profitability | BMY | |
| Gross Margin (TTM) | 73.03% | |
| Operating Margin (TTM) | 6.09% | |
| Pretax Margin (TTM) | 6.09% | |
| Net Profit Margin (TTM) | 10.14% | |
| * Data above as of Mar 31, 2013 | ||
| Valuation | BMY | |
| P/E excluding extraordinary items (TTM) | 49.4x | |
| P/E Normalized (MRFY) | 12.8x | |
| P/Sales (TTM) | 4.4x | |
| P/Tangible book (TTM) | -- | |
| P/Cash Flow (TTM) | 25.7x | |
| * Data above as of May 17, 2013 | ||
| Financial Strength | BMY | |
| Current Ratio (MRQ) | 1.2 | |
| Quick Ratio (MRQ) | 1.0 | |
| LT Debt/Equity (MRQ) | 0.5 | |
| Total Debt/Equity (MRQ) | 0.6 | |
| Payout Ratio (TTM) | 156.9 | |
| * Data above as of Mar 31, 2013 | ||
| Management Effectiveness | BMY | |
| Return on Assets (TTM) | 4.80% | |
| Return on Equity (TTM) | 9.78% | |
| Return on Investments (TTM) | 6.22% | |
| * Data above as of Mar 31, 2013 | ||
| Growth | BMY | |
| Sales (5Yr) | 2.44% | |
| EPS (TTM over TTM) | -60.67% | |
| Dividend Growth (5Yr) | 3.56% | |
| * Data above as of Mar 31, 2013 | ||
| Income Statement | BMY | |
| EBITDA (MRQ) | 674.0M | |
| Earnings before taxes (MRQ) | 674.0M | |
| Net Income (MRQ) | 609.0M | |
| Normalized earnings before taxes (MRQ) | 720.0M | |
| Normalized Net Income (MRQ) | 609.0M | |
| * Data above as of Mar 31, 2013 | ||
| Per Share Data | BMY | |
| EPS excluding extraordinary items (TTM) | 0.88 | |
| EPS Normalized (MRFY) | 3.37 | |
| Rev per share (TTM) | 9.70 | |
| BV per share (MRQ) | 8.32 | |
| Tangible BV per share (MRQ) | -1.56 | |
| Cash per share (MRQ) | 1.54 | |
| Cash flow per share (TTM) | 1.66 | |
| Indicated Annual Dividend (US) | 1.40 | |
| * Data above as of Mar 31, 2013 | ||
| Short Interest | BMY | |
| Shares Short (Current Month) | 29.5M | |
| Short Ratio | 3.1 | |
| Short Interest as % of Float | 1.80% | |
| Shares Short (Prior Month) | 32.1M | |
| * Data above as of Apr 30, 2013 | ||
Company Overview
Company Contact Info
Address
345 Park Avenue
NEW YORK, NY 10154
Telephone
(212) 546-4000Fax
(302) 655-5049